KeyBanc lowered the firm’s price target on Inspire Medical (INSP) to $197 from $216 and keeps an Overweight rating on the shares. The firm notes that underlying MedTech trends appear positive heading into Q2 earnings season, and KeyBanc believes sub-sector underperformance this year has been more attributable to macro uncertainties such as the impact of tariffs. Specifically, the firm’s Key First Look Data has indicated high-single digit volume growth in the hospital category through Q2. KeyBanc continues to view tariffs as the biggest overhang to the group, but consensus estimates at least now incorporate the known base-case impacts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $182 from $200 at Morgan Stanley
- Inspire Medical price target lowered to $149 from $176 at Leerink
- Inspire Medical granted premarket application approval for CGuard Prime
- Buy Recommendation for Inspire Medical Systems Driven by Efficiency and Growth Potential
- Inspire Medical Systems Launches Inspire V for OSA